Photo: Female researcher using a machine in the lab


Ocrelizumab works by targeting a type of immune cell (called a B cell). This helps to reduce the immune response by stopping these cells from attacking and damaging myelin.

Ocrelizumab was licensed by the European Medicines Agency in January 2018 for people with relapsing MS and for people with early primary progressive MS.

In May 2019, after originally rejecting it, NICE approved the use of ocrelizumab for people with early primary progressive MS on the NHS. Over 21,000 people joined our campaign to call for this change. This decision shows how promising research can translate into real world treatment for people with progressive MS.

Ocrelizumab is an intravenous infusion treatment that has been developed by Roche.

Current phase of trial: Licensed

Type of MS: primary progressive and relapsing MS

Find out more about ocrelizumab